Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTDS Extension in Low Back Pain
NCT01125917Phase 3Terminated
- Sponsor
- Purdue Pharma
- Start
- Jun 2004
- Primary completion
- Sep 2005
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of v1003 in chronic low back pain (CLBP), sponsored by Purdue Pharma. Primary endpoint: Number of Participants With Adverse Events (AEs) as a Measure of Safety at 52 weeks. Started Jun 2004; status: terminated.
02
Drugs
v1003
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT01125917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125917.